A phase II study of neoadjuvant immune checkpoint inhibitors in urothelial cancer.
A clinical enabling study of bone-marrow vascular leak measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in healthy subjects and patients with Acute Myeloid Leukaemia (AML).
A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.
A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer.
Early detection of pancreatic ductal adenocarcinoma (PDAC) using a panel of biomarkers.
In set up
Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer.
In follow-up (closed to recruitment)
A randomised, open-label phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer.
MEDI4736 combinations in metastatic renal cell carcinoma.
A Phase II, Double Blind, Randomised, Placebo-Controlled Study of the AKT Inhibitor AZD5363 in Combination with Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer.
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma.
A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder.
Phase II window of opportunity study of short-term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer.
A novel, single arm phase II study for relapsed germ cell tumours with poor prognosis.
A phase II, open label, multicentre, randomised controlled trial comparing hyperthermia plus mitomycin to mitomycin alone, in patients with intermediate risk non-muscle invasive bladder cancer.
IMaging pilot study of the αvβ6 integrin radiotracer [18F]-A20FMDV2 in PAtients with solid Cancer Types.
A randomized Phase II study of Fulvestrant in combination with the dual mTOR inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen receptor-positive advanced or metastatic breast cancer.
A phase II study investigating preoperative bintrafusp alfa in operable urothelial carcinoma of the bladder.
Robotic Surgery After Focal Ablation Therapy.
A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab-Paclitaxel for pancreatic cancer.
A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers.
A phase II, single arm, multicentre trial of triamcinolone with a GnRH analog for castration resistant prostate cancer.